NCT07126990

Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma

• Status: Enrolling By Invitation
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Xiaorong Wu · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Clinical study of a novel oncolytic virus Ad-TD-nsIL12 in the treatment of primary high-grade glioma

Detailed description

This study will conduct two prospective, single-arm, single-center, exploratory clinical trials aimed at assessing the preliminary efficacy and safety of the novel oncolytic adenovirus Ad-TD-nsIL12 in treating primary HGG. Trial 1 will preliminarily evaluate the efficacy and safety of Ad-TD-nsIL12 as neoadjuvant treatment for patients with non-functional zone primary HGG; Trial 2 will preliminarily evaluate the efficacy and safety of Ad-TD-nsIL12 in treating patients with functional zone and thalamic primary HGG, as well as their quality of life.

Conditions

• Glioma

Interventions

Type	Name	Description
BIOLOGICAL	Novel oncolytic virus Ad-TD-nsIL12	Ommaya capsule was placed for intratumoral injection at a dose of 1×10\^10vp

Timeline

• Start date: 2025-02-12
• Primary completion: 2028-08-30
• Completion: 2028-08-30
• First posted: 2025-08-17
• Last updated: 2026-03-23

Locations

1 site across 1 country: China